10-K: ENDRA Life Sciences Inc. Files 10-K Report, Outlines Financials and Strategic Outlook

ENDRA Life Sciences Inc. released its 10-K filing, detailing its financial status, ongoing development of its TAEUS technology, and future strategic plans.

Summary

• ENDRA Life Sciences Inc. has filed its annual 10-K report, highlighting its financial condition and operational activities for the fiscal year ended December 31, 2023.
• The company is focused on developing its Thermo Acoustic Enhanced Ultrasound (TAEUS) technology platform, aimed at improving diagnostic capabilities of ultrasound systems.
• Their first TAEUS application targets the quantification of liver fat for the diagnosis and monitoring of nonalcoholic fatty liver disease (NAFLD).
• As of December 31, 2023, ENDRA had an accumulated deficit of $91.9 million and cash reserves of approximately $2.8 million.
• The company reported a net loss of $10.1 million for 2023, compared to a net loss of $13.2 million in 2022.
• ENDRA is pursuing FDA clearance for its TAEUS FLIP system via the de novo pathway, with a new submission anticipated in the first half of 2025.
• The company has a scheduled pre-submission meeting with the FDA in the second quarter of 2024 and expects to complete necessary clinical studies by the fourth quarter of 2024.
• ENDRA has a CE mark for its TAEUS FLIP system in Europe and is actively marketing in France, the UK, and Germany.
• The company is also exploring other potential clinical applications for its TAEUS technology, including temperature monitoring for thermoablative surgery, vascular imaging, and tissue perfusion.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there is progress in technology development and regulatory approvals in Europe, the company faces significant financial challenges, delays in FDA approval, and a material weakness in internal controls. The need for additional capital and the history of losses temper the positive aspects.

Positives

• The company has made progress in obtaining regulatory approvals, securing a CE mark for its TAEUS FLIP system in Europe.
• ENDRA is actively marketing its product in key European markets, including France, the UK, and Germany.
• The company is actively pursuing FDA clearance for its TAEUS FLIP system, with a new submission expected in the first half of 2025.
• The company has reduced its net loss from $13.2 million in 2022 to $10.1 million in 2023.
• ENDRA is exploring multiple potential applications for its TAEUS technology, expanding its market opportunities.

Negatives

• ENDRA has a history of operating losses and an accumulated deficit of $91.9 million.
• The company has limited cash reserves of approximately $2.8 million as of December 31, 2023.
• The company has not yet generated revenue from its TAEUS technology.
• The FDA de novo submission process has been delayed, with a new submission not expected until the first half of 2025.
• The company has identified a material weakness in its internal control over financial reporting.

Risks

• The company has a history of operating losses and may never achieve profitability.
• ENDRA's success is heavily dependent on the successful development and commercialization of its TAEUS technology.
• The TAEUS platform applications may not achieve adequate market acceptance.
• The company may not remain commercially viable if there is inadequate reimbursement for its products.
• ENDRA depends on third parties for design, manufacturing, and regulatory approvals.
• The company faces intense competition in the medical imaging market.
• Failure to obtain and maintain necessary regulatory clearances or approvals could harm the business.
• The company is subject to risks associated with doing business outside of the United States.
• The company depends on its senior management team, and the loss of key employees could harm the business.
• The company may be subject to product liability claims and regulatory proceedings.
• The company may be subject to intellectual property litigation.
• The company may not be able to raise sufficient capital to continue operations.

Future Outlook

ENDRA anticipates completing necessary clinical studies by the fourth quarter of 2024 and submitting a new de novo request to the FDA in the first half of 2025. The company also plans to expand its marketing efforts in Europe and begin staffing its sales efforts in the United States after FDA approval. ENDRA is also exploring additional applications for its TAEUS technology.

Management Comments

• Management is actively exploring additional sources of liquidity and may seek to raise capital through various means.
• Management believes that the TAEUS technology has the potential to add new capabilities to conventional ultrasound and other types of capital equipment.
• Management intends to price the initial liver TAEUS system at approximately $65,000.

Industry Context

The document highlights ENDRA's position in the medical imaging market, particularly in the ultrasound sector. The company is aiming to address the unmet need for cost-effective and accurate diagnostic tools, especially for conditions like NAFLD. The document also notes the growing market for ultrasound devices and the increasing demand for non-invasive diagnostic methods.

Comparison to Industry Standards

• The document mentions that the global diagnostic ultrasound device market was valued at $7.7 billion in 2023, with an anticipated CAGR of 4.07% from 2022 to 2030, indicating a growing market for ultrasound technology.
• The company estimates its addressable market to include approximately 700,000 ultrasound systems currently in use worldwide, suggesting a significant potential market for its TAEUS technology.
• The document notes that CT systems cost approximately $1 million and MRI systems can cost up to $3 million, while smaller portable ultrasound systems cost as little as $5,000, highlighting the cost-effectiveness of ultrasound technology, which ENDRA aims to enhance.
• The company is competing with major players in the medical imaging market, such as Royal Philips, Siemens AG, and Fujifilm Corporation, who also manufacture and sell ultrasound equipment, as well as makers of surgical biopsy tools and surgical temperature probes.
• The document mentions that the global radiofrequency ablation devices market is expected to surpass $10.2 billion by 2030, representing a CAGR of 11%, indicating a significant market for ENDRA's thermoablation application.

Related Party Transactions

• In 2023, a director, Anthony DiGiandomenico, purchased shares and warrants in a public offering.
• In 2023, the company entered into a consulting agreement with director Alex Tokman.
• In 2023, the company issued restricted stock to PatentVest, Inc., a subsidiary of MDB Capital Holdings, LLC, where two directors have affiliations.

Stakeholder Impact

• Shareholders face the risk of dilution due to potential future capital raises.
• Employees may be affected by potential cost-cutting measures if the company faces financial difficulties.
• Customers (healthcare providers) may benefit from the potential cost-effectiveness and improved diagnostic capabilities of the TAEUS technology.
• Suppliers may be impacted by the company's financial stability and ability to pay for components and services.
• Creditors face the risk of non-payment if the company is unable to secure additional financing.

Next Steps

• ENDRA will continue to pursue FDA clearance for its TAEUS FLIP system via the de novo pathway.
• The company will complete necessary clinical studies by the fourth quarter of 2024.
• ENDRA will submit a new de novo request to the FDA in the first half of 2025.
• The company will continue to expand its marketing efforts in Europe.
• ENDRA plans to begin staffing its sales efforts in the United States after FDA approval.
• The company will continue to explore additional applications for its TAEUS technology.

Key Dates

Keywords

TAEUS, ultrasound, NAFLD, liver fat, medical imaging, thermoacoustic, FDA, CE mark, regulatory approval, clinical studies, medical devices, healthcare technology